Physician profile
Michael Weng
NPI 1396837480
$2,158.01
in general payments reported to CMS, 2019-2025
24 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $182 · 2021: $411 · 2022: $204 · 2023: $357 · 2024: $295 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $874.00 | 2020-2025 | Tricera Handpiece, Tapestry, Juggerknotless Soft Anchor |
| Depuy Synthes Sales INC. | $222.30 | 2019-2025 | Milagro, Truespan Orthocord, Monovisc |
| Smith+Nephew, INC. | $127.04 | 2019-2025 | Bone Anchors With Arthroscopic Delivery System |
| Stryker Corporation | $106.30 | 2023-2024 | Aequalis Ascend Flex, Aequalis Perform Reversed, Aequalis Flex Revive |
| Ferring Pharmaceuticals INC. | $105.93 | 2021-2025 | Euflexxa |
| Horizon Therapeutics Plc | $92.99 | 2019-2021 | |
| Pacira Therapeutics, INC. | $90.91 | 2019-2021 | |
| Bioventus LLC | $72.68 | 2019-2025 | Durolane, Durolane |
| Zyla Life Sciences, INC. | $61.63 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $57.56 | 2024-2025 | |
| Avanos Medical | $52.29 | 2019-2022 | |
| Goode Surgical INC | $47.45 | 2020 | |
| Vericel Corporation | $30.17 | 2021-2024 | Maci |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.02 | 2025 | Xifaxan |
| Fidia Pharma USA INC. | $27.22 | 2023 | Hymovis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $25.01 | 2024 | Ibsrela |
| Hologic Sales and Service, LLC | $24.06 | 2024 | Aptima |
| Impactortho, INC. | $19.71 | 2025 | |
| Dynasplint Systems INC. | $17.92 | 2021 | |
| Janssen Biotech, INC. | $16.65 | 2024 | Stelara |
| Dexcom, INC. | $16.35 | 2025 | Dexcom G6 Transmitter |
| Team_makena_llc | $14.30 | 2020 | |
| Abbott Laboratories | $14.02 | 2023 | Proclaim |
| Illuminoss Medical, INC. | $11.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.